Recent

% | $
Quotes you view appear here for quick access.

China Biologic Products, Inc. Message Board

  • z101789 z101789 Nov 28, 2012 1:44 PM Flag

    should go to 20 based on factor VIII

    And then to 40 if the Baxter trial shows that IVIG helps Alzheimer's disease

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Z101789

      I need several more positive posts from you, so we can pump up this board to the level that the positive net income of this puppy deserves
      .
      Example $2.19 earnings per share times 10 PE=$21.90 per share.

      Sentiment: Strong Buy

    • What is IVIG? How is this company related to BAXTER?

      Thanks

      • 3 Replies to prphilip
      • Written By: Aaron Saenz
        Posted: 04/15/10 1:24 PM
        Email Story Baxter’s New Treatment for Alzheimer’s Delays, Partly Reverses Disease!

        Baxter announced that immunotherapy product Gammagard is effective in treating Alzheimer's.
        There are few diseases that are as terrifying as Alzheimer’s. Losing your memory, your comprehension, and knowing all the while that your life is slowly fading from your mind. It’s a very scary reality for the 30 million people on the planet who have it. To date there are no real ways to cure the illness. Luckily, help may be on the way. Baxter International (NYSE:BAX) released the results from its phase II clinical trial on April 13th, demonstrating that their Gammagard product could help stop the loss of brain cells in Alzheimer’s patients. That’s phenomenal! This is a treatment that could stop, maybe even reverse, some of the progression of Alzheimer’s disease, and it’s already been tried in humans. It will likely be several years until Gammagard is ready to hit the market (there are still phase III trials to pass) but we have gotten closer to an effective means of slowing or stopping Alzheimer’s in its tracks, and that’s incredible news.

        The recently completed Baxter study, which was performed in cooperation with the Weiss Cornell Medical Center, looked at 14 patients over 18 months using MRI scans to record the rate of brain cell loss. According to their press release, those patients on Gammagard experienced less loss of brain cells (measured by swelling in areas of the brain) than those patients on placebo. Cognition and function was also better for Gammagard patients than those on placebo. These results are pretty amazing. Losing fewer brain cells is high on my list of positive effects for any drug and preventing Alzheimer’s related memory and cognition loss is also damned important. According to Bloomberg, there were even some patients that showed noticeable reversal in Alzheimer’s symptoms. One patient, a pianist, was formerly only able to remember and play about four songs. After the 18 month trials, family members reported that the patient had started to learn new songs. That’s news that brings hope to Alzheimer’s patients everywhere and would certainly make selling Gammagard very easy.

        The market for Alzheimer’s drugs is already in the billions. Aricept, from Pfizer, had sales in excess of $3 billion last year, and Forest Labs sold $950 million of their product, Numenda. The market is driven by the 30 million Alzheimer’s patients in the world, 5 million or so in the US. According to the CDC there may be around 13 million patients in the US by 2050. Medicare spent $91 billion in Alzheimer’s related expenses in 2005 alone. The world population is continuing to get older, and Alzheimer’s is an age-related disease. Overcoming it will be a major hurdle in our pursuit of longevity.

        Gammagard is a immunotherapy product (intravenous immunoglobulin or IVIG) developed from thousands of human plasma donations. It’s been FDA approved (for immunotherapy) and on the market since the 90s in various forms. Many believe that Alzheimer’s may be caused by the buildup of amyloid plaque and related inflammation on the brain, and Gammagard contains amyloid fighting antibodies. In the phase II trials nurses traveled to the residences of patients and gave them Gammagard intravenously with regularly scheduled check ups and brain scans to measure effect. Those on placebo were switched to the drug after six months.

        According to Baxter, the recently completed phase II trial for Gammagard is the first that tracked the trifecta for Alzheimer’s treatment: neuro-imaging, cognition, and brain function. Baxter plans on continuing with two phase III trials, the first of which is already started, and the second will begin by late 2010. This second phase III trial will continue to use MRI scans. The first phase III trial will focus on cognition and function and is part of the Gammaglobulin Alzheimer’s Partnership (GAP) study. 360 patients at 35 sites across the country (12 more sites pending in the US and Canada) will be studied for 18 months to see how Gammagard affects the progression of Alzheimer’s Disease. GAP is still actively recruiting patients, and those interested can check their website for eligibility. Because these studies will take at least 18 months to run, the earliest we will see results is likely to be 2012 for the GAP study and 2013 for the other phase III trials. In other words, there are years before we could see Gammagard approved by the FDA.

        That being said, it’s important to note that Baxter is not the only company developing an IVIG drug for Alzheimer’s. Octapharma has its own phase II trial for octagam, a product much like Gammagard in basic composition. According to ClinicalTrials.gov, Pfizer and GSK also have intravenous treatments for Alzheimer’s Disease in the pipeline, PF-04360365 and GSK933776 respectively, both of which are anti-amyloid, though not necessarily immunoglobulin. Despite the competition, Gammagard is arguably the closest of these products to obtaining FDA approval and introduction into the market though Baxter’s stock rise after its announcement on April 13th was surprisingly small

        Sentiment: Strong Buy

      • IVIG constitutes 44% of CBPO's revenues. The price of IVIG in China is approximately 20% of that in western countries, mostly due to low production costs. You can easily see the potential profits from exports, or if acquired by a global pharmaceutical company.

        Sentiment: Strong Buy

      • IVIG is the abbreviation for intravenous immunoglobulin, one of the products made from plasma by CBPO and other plasma companies, mostly Baxter, CSL, and Griffols. Baxter's IVIG is called gammagard, which is currently in phase III trials for Alzheimer's disease. See link:
        http://www.bloomberg.com/news/2012-07-17/baxter-s-gammagard-shows-alzheimer-s-benefit-in-study.html

        Sentiment: Strong Buy

 
CBPO
109.24+1.37(+1.27%)May 22 4:00 PMEDT